Dr. George Yaghmour's Guide to Living With Chronic Lymphocytic Leukemia

Many chronic lymphocytic leukemia (CLL) patients experience significant emotional distress after a diagnosis, but education, honest expectation‑setting, and detailed risk stratification help shift the experience from fear to clarity, especially since many patients do not need treatment right away.

AI tools are becoming part of how patients learn about chronic lymphocytic leukemia (CLL), but they can introduce confusion or misinformation; physicians increasingly find themselves clarifying or correcting what patients read online.

BTK inhibitors and BCL-2 inhibitors have become the preferred first-line treatments for many patients with CLL due to their effectiveness and generally more favorable side-effect profiles.

Treatment for chronic lymphocytic leukemia (CLL) begins only when symptoms or lab findings demand it. For managing this chronic disease, quality of life becomes central.